Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

Drugs in Context

article

Shinichi Makita¹  Katsuaki Imaizumi²  Saiko Kurosawa³  Kensei Tobinai¹ 

[1] Department of Hematology, National Cancer Center Hospital;Clinical Trial Coordination Office, National Cancer Center Hospital;Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital

关键词: axicabtagene ciloleucel;    B-cell non-Hodgkinlymphoma;    CAR-T;    CD19;    chimeric antigen receptor;    diffuse largeB-cell lymphoma;    lisocabtagene maraleucel;    tisagenlecleucel.;   

DOI  :  10.7573/dic.212567

学科分类：社会科学、人文和艺术（综合）

来源: C S F Medical Communications Ltd.

【 摘 要 】

B-cell non-Hodgkin lymphoma (NHL) is the most frequenthematologic malignancy. Despite the refinement ofchemoimmunotherapy, a substantial number of patientsexperience chemorefractory disease. Anti-CD19 chimericantigen receptor (CAR) T-cell therapy is considered the mostpromising and effective therapy to overcome chemorefractoryB-cell NHL. Based on the promising results obtained frompivotal trials, the US Food and Drug Administration andEuropean Medicines Agency approved anti-CD19 CAR T-celltherapy for relapsed/refractory diffuse large B-cell lymphoma.Nonetheless, there remain several controversial issues andproblems awaiting solutions, including optimal managementof toxicities, overcoming relapsed/refractory disease afterCAR T-cell therapy, and improving CAR-T manufacturingplatform. Definite unmet medical needs among patients withchemorefractory B-cell NHL still exist. CAR T-cell therapy mightbe a game changer that can defeat chemorefractory B-cellNHL, and further clinical development is warranted. In thisreview, we summarize the recent clinical developments, clinicalimplications, and perspectives of CAR T-cell therapy, focusing onB-cell NHL.

【 授权许可】

CC BY-NC-ND